<DOC>
	<DOCNO>NCT00141765</DOCNO>
	<brief_summary>The purpose study determine whether high dosage chemotherapy improve chance survive cancer .</brief_summary>
	<brief_title>Study High-Dose Chemotherapy With Bone Marrow Stem Cell Transplant Rare Poor-Prognosis Cancers</brief_title>
	<detailed_description>This phase II trial design provide transplant option patient rare poor-prognosis cancer . The protocol open patient metastatic relapse cancer probability remain free progressive disease one year bring remission &lt; 25 % . Patients eligible study diagnose form cancer lead death 75 % time treated standard therapy dose chemotherapy and/ radiation therapy . Under treatment intensification protocol expectation one year progression-free survival group patient rise 40 % . Patients eligible protocol follow one year post-transplant . Patients alive free progressive disease end period consider success .</detailed_description>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Fibrosarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Patients must ineligible IRBapproved myeloablative regimen , 21 year old young , must histologicallyconfirmed Wilms ' tumor , liver cancer , recurrent brain tumor childhood , nasopharyngeal carcinoma , fibrosarcoma , desmoplastic small round cell tumor , germ cell tumor small round cell tumor , : 1. metastatic &lt; 25 % cure rate conventional treatment ; 2. progress prior chemotherapy &lt; 25 % salvage rate nonmyeloablative therapy . Disease status : Within 3 week initiation protocol , patient must : 1. complete good partial remission ( section 7.4 ) ; 2. `` chemosensitive '' tumor , define &gt; 50 % decrease least one measurable tumor parameter attributable prior chemotherapy , without evidence progressive disease parameter . Prior chemotherapy : Before entry protocol , patient must derive maximal benefit conventional , i.e. , nonmyeloablative , dose combination chemotherapy . Conventional therapy continue either complete remission achieve , benefit nonmyeloablative dosing appreciate , toxicity conventional therapy perceive limiting absence stem cell rescue . The cancer must prove sensitive alkylating agent . This mean , addition , part , appropriate chemotherapy protocol specific cancer question , patient must receive responded minimum : 1 . 2 course highdose cyclophosphamide , total &gt; 4200 mg/m2 ; 2. course highdose ifosfamide total &gt; 12 gm/m2 . 3 . 1 course `` ) '' , plus 1 course ' b ) '' . 4 . Equivalent high dose alkylating agent describe 3.3 , b , c. Patients must adequate renal hepatic , cardiac function ( section 4.44.6 ) . Patients must meet least one follow stem cell requirement ( Peripheral blood collection prefer available option ) : 1 . Harvested bone marrow must contain 1 x 108 nucleated cell per kg body weight , , 2 . Peripheral blood collection include least 2 x 106 CD34+ cells/kg . Informed consent must sign indicate patient and/or parental awareness investigational nature program</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>